Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Results from a preclinical in vivo study have shown potential for Medicure's MC-1 in the treatment of hypertriglyceridemia, a disorder commonly associated with type 2 diabetes, insulin resistance and obesity.
Subscribe to our email newsletter
The triglyceride-lowering effects of MC-1 were evaluated in an industry-standard cholesterol model. The in-vivo model involves feeding a high cholesterol diet to the subject animals thereby inducing high levels of triglycerides, total cholesterol and LDL cholesterol.
Treatment with MC-1 (10mg/kg) for seven weeks was associated with a 72% reduction in triglyceride levels versus control. In addition to the significant improvement shown relative to placebo, MC-1 also demonstrated an improvement versus an approved, widely prescribed triglyceride reduction agent in this model.
Medicure’s lead combination product, MC-4232, a combination of MC-1 and an ACE inhibitor, is currently being investigated in a trial, named MATCHED, in patients with diabetes and hypertension. One of the trial’s primary endpoints is metabolic function, which includes the measurement of triglyceride reduction.
“Earlier clinical studies have shown MC-1’s ability to reduce other important metabolic markers such as HbA1c, a marker of hyperglycemia. These new triglyceride findings further strengthen our belief that our combination drug, MC-4232 could represent a major improvement in the treatment of patients with co-existing diabetes and hypertension,” said Dr Albert Friesen, Medicure’s president and CEO.